Nadine C. Lamla

Lead within therapeutic area oncology the creation and execution of the global commercial strategy for obrixtamig (DLL3/CD3 T-cell engager) from clinical development phases to launch in small cell lung cancer and extrapulmonary neuroendocrine carcinoma indications

Lead global pipeline marketing in therapeutic area cardio renal metabolic for survodutide (GLP1/GCGR agonist) in obesity and MASH indications

Lead global cardiology strategy and activities of two heart failure indication launches of empagliflozin (SGLT2 inhibitor) within the Lilly and Boehringer Ingelheim Alliance

Build and lead neurology franchise of Lilly Germany managing the marketing team directly and leading the launch of two new brands

Lead global strategy and activities of linagliptin (DPP-4-Inhibitor) within the Eli Lilly and Boehringer Ingelheim Alliance

Lead regional strategy and implementation of activities to launch the first SGLT2i in type 2 diabetes in the Asia Pacific region compassing 13 countries and leading the cross-functional Integrated Brand Value Team

Lead primary care, women’s health, gastroenterology, central nervous system and lifecycle management franchise managing the marketing team and leading implementation of activities with sales forces, partnerships and alternative channels.

Lead global activities of growth hormone product incl. launch of a new patient device.

Lead strategy and execution of contraceptive patch in private and institutional market segments managing the marketing team and implementation of activities with sales force, digital and PR as well as DTC.

Specialized in Marketing, Foreign Trade, Controlling and International Projects Award for Best Master Thesis of the Year 2003